| Autor: |
Yang, Zhen‐Chong, Du, Chao‐Chao, Liu, Ting, Liu, Li‐Ting, Chen, Qiu‐Yan, Guo, Shan‐Shan, Mai, Hai‐Qiang |
| Předmět: |
|
| Zdroj: |
Head & Neck; Jan2022, Vol. 44 Issue 1, p113-121, 9p |
| Abstrakt: |
Background: To evaluate whether patients with post‐treatment metastasis are suitable for GP first‐line palliative chemotherapy (PCT) after undergoing GP IC. Methods: Seven hundred and forty‐six patients with post‐treatment metastasis after undergoing GP IC were eligible. Survival outcomes were compared. Results: Significant differences in survival rates were observed between patients treated with GP and non‐GP chemotherapy (2‐year progression‐free survival [PFS]: 0.7% vs. 9.7%). We investigated survival outcomes of patients treated with GP PCT within 2 years after undergoing GP IC, treated with GP PCT 2 years after undergoing GP IC, and those of non‐GP PCT patients (2‐year PFS: 0.0%, 2.3%, 9.7%). However, there was no difference in the 2‐year PFS between the patients that received GP PCT 2 years after undergoing GP IC and the non‐GP PCT treated patients. Conclusions: GP is not recommended for patients that have received GP IC within 2 years. Two years after undergoing GP IC, GP can be considered. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text